1.80
-0.17(-8.63%)
Currency In USD
| Previous Close | 1.97 |
| Open | 1.97 |
| Day High | 1.97 |
| Day Low | 1.8 |
| 52-Week High | 3.19 |
| 52-Week Low | 0.89 |
| Volume | 398,860 |
| Average Volume | 284,526 |
| Market Cap | 53.9M |
| PE | -2.17 |
| EPS | -0.83 |
| Moving Average 50 Days | 1.88 |
| Moving Average 200 Days | 1.99 |
| Change | -0.17 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $147.54 as of July 01, 2025 at a share price of $1.8. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $518.73 as of July 01, 2025 at a share price of $1.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
GlobeNewswire Inc.
7 hours ago
As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid (CSF) in all participants currently enrolled is now
Gain Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Jun 10, 2025 12:00 PM GMT
BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
GlobeNewswire Inc.
May 29, 2025 12:45 PM GMT
BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ther